Nanoproduction
Maretti E, et al. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability. Int J Pharm. 2016, 511, 669-679. [Link]
Civallero C, et al, Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery, Blood 2015 126:4851 [Link]
Belletti D, et al, Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach, Eur J Pharm Sci, 2017, 107, 230-239. [Link]
Belletti D, et al., PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity, Eur J Pharm Biopharm, 2016, 99, 7-17. [Link]
Valenza M, et al, Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice, EMBO Molecular Medicine, 2015, 7, 1547-1564.[Link]
Pederzoli F, et al. Nanoimaging: Photophysical and pharmaceutical characterization of poly-lactide-co-glycolide nanoparticles engineered with quantum dots, Nanotechnology, 2015, 27, n. 015704. [Link]
Tosi G, et al., Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport. J Control Rel, 2014, 177, 96-107. [Link]
Voltan R et al, Nanoparticles engineered with rituximab and loaded with nutlin-3 show promising therapeutic activity in B-leukemic xenografts, Clin Canc Res, 2013, 19, 3871-3880. [Link]
Truzzi E et al. Self-assembled lipid nanoparticles for oral delivery of heparin-coated iron oxide nanoparticles for theranostic purposes. Molecules, 2017, 22, n.963. [Link]
Nicolini V, et al, SiO2-CaO-P2O5 bioactive glasses: A promising curcuminoids delivery system. Materials, 2016, 9, 290-300. [Link]
Shruti S, et al. Curcumin release from cerium, gallium and zinc containing mesoporous bioactive glasses. Microporous and Mesoporous Materials, 2013, 180, 92–101. [Link]
Belletti D, et al., Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach, Eur J Pharm Sci, 2017, 230-239. [Link]
Belletti D, et al. Exploiting the versatility of Cholesterol in nanoparticles formulation, Int J Pharm. 2016, 511, 331-40. [Link]
Salvalaio M, et al. Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders. PLoS One. 2016, 11, e0156452. [Link]
Belletti D, et al. PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity, Eur J Pharm Biopharm, 2016, 99, 7-17. [Link]
Ruozi B, et al. PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury, Mol Neurobiol, 2015, 52, 899-912. [Link]
Vilella A, et al, Endocytosis of nanomedicines: The case of glycopeptide engineered PLGA nanoparticles, Pharmaceutics, 2015, 7, 74-89. [Link]
Belletti D, et al. Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma, Int J Pharm, 2015, 490, 85-93. [Link]
Monsalve Y., et al. PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting, Nanomedicine, 2015, 10, 1735-1750. [Link]
Chhabra R, et al., Application of polymeric nanoparticles for CNS targeted zinc delivery in vivo, CNS and Neurological Disorders - Drug Targets, 2015, 14, 1041-1053. [Link]
Riva G, et al., Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma, Haematologica, 2015, 100, e467-e470. [Link]
Vilella A, et al., Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution, J Control Rel, 2014, 174, 195-201. [Link]
Tosi G, et al, Brain-targeted polymeric nanoparticles: In vivo evidence of different routes of administration in rodents, Nanomedicine, 2013, 8, 1373-1383. [Link]
Tosi G, et al. Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine, 2012, 7, 365-382 [Link]
Tosi G, et al Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier, Nanomedicine, 2011, 6, 423-436. [Link]
Grabrucker, AM, et al., Development of novel Zn2+ loaded Nanoparticles designed for cell-type targeted drug release in CNS neurons: In vitro evidences, PLoS ONE, 2011, 6, e17851. [Link]
Ruozi B, et al, Immunoliposomal systems targeting primary effusion lymphoma: In vitro study. Nanomedicine, 2010, 5, 1051-1064. [Link]
Tosi G, et al. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J Control Rel, 2010, 145, 49-57. [Link]
Vergoni AV, et al. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution, Nanomedicine: Nanotechnology, Biology, and Medicine, 2009, 5, 369-377. [Link]
Tosi G, et al., Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123, J Control Rel, 2007, 122, 1-9. [Link]
Costantino L, et al. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier, J Control Rel, 2005, 108, 84-96. [Link]